Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT02930837

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02930837
Other papers using this trial's data
  • Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China Stroke and vascular neurology, 2020-09 DOI, PubMed 32467323, PMC7548519 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02930837. Allocation not applicable; no masking; primary purpose treatment. Start 2016-11-15 (actual); primary completion 2017-12-11 (actual). Results posted on 2019-08-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
Condition
Stroke
Intervention (Drug)
alteplase
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct02930837
Content hash
2c6cd7d16d885200783b90cb9db6d96390dc165eea3cac79bf3d86565bcaad11